Naz Rahman
Stock Analyst at Maxim Group
(0.37)
# 3,994
Out of 4,711 analysts
37
Total ratings
17.86%
Success rate
-38.71%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.36 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.10 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.75 | +357.14% | 7 | Nov 13, 2024 | |
| SLXN Silexion Therapeutics | Initiates: Buy | $9 | $2.44 | +268.85% | 1 | Nov 1, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $5.30 | - | 2 | Oct 24, 2024 | |
| VRPX Virpax Pharmaceuticals | Downgrades: Hold | n/a | $0.33 | - | 4 | Oct 9, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.89 | +238.64% | 1 | Jul 26, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $120 | $42.25 | +184.02% | 4 | Jun 4, 2024 | |
| QNRX Quoin Pharmaceuticals | Maintains: Buy | $15 → $4 | $0.57 | +602.99% | 2 | Mar 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Hold | n/a | $397.27 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.29 | +1,258.70% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.85 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.38 | +262.32% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $20 | $3.39 | +489.97% | 2 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.86 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $4.73 | +26.85% | 1 | Feb 25, 2022 |
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.36
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.10
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.75
Upside: +357.14%
Silexion Therapeutics
Nov 1, 2024
Initiates: Buy
Price Target: $9
Current: $2.44
Upside: +268.85%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.30
Upside: -
Virpax Pharmaceuticals
Oct 9, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.33
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.89
Upside: +238.64%
Viking Therapeutics
Jun 4, 2024
Reiterates: Buy
Price Target: $120
Current: $42.25
Upside: +184.02%
Quoin Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $15 → $4
Current: $0.57
Upside: +602.99%
Vertex Pharmaceuticals
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $397.27
Upside: -
Dec 8, 2023
Initiates: Buy
Price Target: $4
Current: $0.29
Upside: +1,258.70%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.85
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $1.38
Upside: +262.32%
May 11, 2023
Maintains: Buy
Price Target: $13 → $20
Current: $3.39
Upside: +489.97%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.86
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $4.73
Upside: +26.85%